Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis

Fernández-Sueiro, José Luís; Willisch, Alfredo; Pértega-Díaz, Sonia; Tasende, José Antonio Pinto; Fernández-López, Jesús Carlos; Villar, Natividad Oreiro; Galdo, F.; Blanco, Francisco J.

doi:10.1002/acr.20017

Cited by 55 publications

(38 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study, including 2,044 consecutive patients with SpA, showed that primary AS had more severe axial involvement than those with spondylitis associated with psoriasis or IBD, while functional capacity, disease activity and quality of life were comparable among the groups studied [14]. Moreover, to support the assumptions that an equivalency between axial PsA and AS may not hold up, previous studies showed that the Bath Ankylosing Spondylitis Disease Activity score (BASDAI) in PsA was significantly lower than AS, correlated poorly with external indicators of disease activity [15] and may be influenced by the peripheral involvement, showing again the difference between these two conditions [16]. All these interesting data confirmed, to some extent, that axial PsA is quite different to the classical AS and is usually less severe [17].…”

Section: Introductionmentioning

confidence: 65%

See 1 more Smart Citation

Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?

Lubrano

Spadaro

2012

Clin Rheumatol

View full text Add to dashboard Cite

This article summarizes the state of the art of axial involvement in psoriatic arthritis (axial PsA). The definition and measurement of axial disease in PsA still remain problematic, and this, in turn, could affect the best approach of recognition and treatment of this intriguing subset of the psoriatic disease. Axial PsA has been studied over the last few years looking at the difference in function and radiological finding compared to ankylosing spondylitis (AS), trying to differentiate it from a coincidental AS with psoriasis. Finally, this review has described the diagnosis and treatment of axial PsA reporting the data obtained from the literature.

show abstract

Section: Introductionmentioning

confidence: 65%

“…The cutoff point (BASDAI score >4) for the definition of moderate to severe disease activity has been considered an appropriate criterion adopted from AS for axial disease in PsA [36], although the BASDAI in PsA may be influenced by the peripheral involvement [16].…”

Section: Treatment Of Axial Spamentioning

confidence: 99%

Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?

Lubrano

Spadaro

2012

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…First study by Taylor and Harrison showed that BASDAI was significantly lower in PsA than AS and did not correlate well with external indicators of disease activity [12]. The other study by Fernandez Sueiro et al found that the BASDAI performed similar in both peripheral and axial PsA however has not been found as a good instrument to assess disease activity in axPsA [13].…”

Section: Discussionmentioning

confidence: 99%

“…One of the composite indices for evaluating disease activity is BASDAI which is the most accepted and widely used tool in daily practice in patients with AS. Until now, only two previous studies assessed the validity of BASDAI as an indicator of disease activity in PsA [12,13]. First study by Taylor and Harrison showed that BASDAI was significantly lower in PsA than AS and did not correlate well with external indicators of disease activity [12].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis

Kılıç

Nas

et al. 2014

Clin Rheumatol

View full text Add to dashboard Cite

The aim of this study was to compare the discriminative ability of Ankylosing Spondylitis Disease Activity Score (ASDAS) with Bath Ankylosing Spondylitis Activity Disease Activity Index (BASDAI) and other clinical disease activity parameters in patients with axial psoriatic arthritis (axPsA). Patients with axPsA were recruited from Erciyes Spondyloarthritis Cohort (ESPAC) and Anatolian Group for the Assessment in Rheumatic Disease (ANGARD) cohort and were assessed for BASDAI, ASDAS, BASFI (Bath Ankylosing Spondylitis Functional Index), Ankylosing Spondylitis Quality of Life (ASQoL), and visual analog scale (VAS) pain. The discriminant ability of ASDAS-C-reactive protein (-CRP) and ASDAS-erythrocyte sedimentation rate (-ESR) was assessed using standardized mean differences between patients with high and low disease activity. Fifty-four patients with axPsA were included in the study. Both ASDAS scores showed good discriminative ability between high and low disease activity states. Both ASDAS versions and BASDAI had relatively high area under the curve (AUC) according to ASAS partial remission, patient and physician global assessments in receiver operating characteristic (ROC) curve analysis. There was no significant difference between AUC scores for the models that compared ASDAS-CRP and ASDAS-ESR with BASDAI for each individual definition of disease activity states. ASDAS versions and BASDAI showed good similar discriminative ability between high and low disease activity as reflected by the AUC analysis in axPsA. The cutoff values for inactive disease and high disease activity were relatively similar to predefined cutoff values for AS. Further, prospective validation is now required to identify the appropriate assessment tools and cutoff values in axPsA.

show abstract

Outcome measures in psoriatic arthritis: Where next?

Hackett

Coates

2022

Musculoskeletal Care

View full text Add to dashboard Cite

Objective: To provide an overview of commonly used outcome measure in psoriatic arthritis (PsA).Background: PsA is a heterogenous inflammatory arthritis, associated with psoriasis that affects between 0.1% and 2% of the population and approximately one in three patients with psoriasis. Psoriatic arthritis places a significant burden on patients' overall quality of life and is associated with a range of comorbidities. Although assessment of patients and monitoring of symptoms has greatly improved over the last 2 decades, capturing disease activity in this multisystem disease remains challenging. Previous efforts have traditionally focussed on assessment of individual disease domains, however recent evidence suggests that composite measurements, particularly those incorporating patient reported outcomes may not only help monitor disease activity more accurately, but also help in accurately validating therapy outcomes in PsA patients.Purpose: This review discusses currently used outcome measurements in PsA and also highlights the importance of emerging measurements such as biomarkers and their possible role in capturing treatment response. K E Y W O R D S outcomes measurements, PROM, psoriatic arthritis 1 | INTRODUCTION Psoriatic arthritis (PsA) is a heterogenous condition with musculoskeletal involvement, manifesting as a variety of symptoms including arthritis, dactylitis, enthesitis and axial involvement (Coates and Helliwell, 2017). In addition to musculoskeletal symptoms, patients with PsA have other symptoms such as nail disease, which affects between 63% and 83% of patients (Nieradko-Iwanicka, 2017). Along with the varied nature of symptoms, the repercussions on patients are equally as diverse. Patients with PsA have an increased risk of comorbidities such as cardiovascular disease, metabolic syndromes, depression, inflammatory bowel disease and anxiety. In order to measure the impact of PsA on patients, a range of outcomes measures have been developed to ascertain disease impact and help monitor response to treatment in both clinical trials and the realworld settings. Despite the development of a range of outcome measures for patients, agreement as to the exact measure that should be utilized remains a challenge. Recent recommendations from the TIght Control Of Psoriatic Arthritis (TICOPA) trial have highlighted the need and importance of regular assessment of disease activity by clinicians, as well as the critical role patients play in capturing their own concerns (Coates et al., 2015). To capture these outcome measurements, The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) PsA working group developed a This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis

Cited by 55 publications

References 17 publications

Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?

Axial psoriatic arthritis: an intriguing clinical entity or a subset of an intriguing disease?

Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis

Outcome measures in psoriatic arthritis: Where next?

Contact Info

Product

Resources

About